JUL 10, 2018 10:30 PM PDT

The ALFRED Analysis for Cancer Predisposition Genes

WRITTEN BY: Mauri Brueggeman

A group of researchers in Spain methodically evaluated exome data from 10,000 tumors in an attempt to identify cancer predisposition genes as well as verify their statistical method.  They created a statistical method called ALFRED, which stands for allelic loss featuring rare damaging.  They used this method to evaluate Alfred Knudson’s classic “two hit” postulation which originated in 1971.  The article was published July 4, 2018 in Nature Communications.

Knudson was a geneticist researching retinoblastoma and his interest focused on the loss of function mechanism based on the knowledge that most tumor suppressor genes are recessive in nature.  This is what led him to propose the “two hit” hypothesis as a mechanism for the de novo development of cancer. 

The ALFRED model utilizes a principal component analysis to cluster common variants in cancer patients.  Then using two different test types, they quantify rare damaging germline variants with loss of heterozygosity events (termed allelic imbalance) compared to matched non-tumor samples from each patient which leads to an ALFRED P-value.  ALFRED was applied to 10,043 tumor exomes which had sequencing data as part of The Cancer Genome Atlas project. 

After evaluating the data against previously known cancer predisposition genes from recent literature reviews and the Cancer Gene Census, the group determined that these showed increased numbers of rare damaging germline variants with high frequency of allelic imbalance.  They also evaluated somatic cancer genes for germline risk variants; their findings indicate that there are a few genes that are affected by somatic changes but may also further cancer development because of rare germline variations.

The research points to potential new germline cancer predisposition variants including NSD1, MYH1, NOP56, PRPF8, INO80, ANK2, and ATM.

More significant research is needed to explore the use of a statistical method like ALFRED to further classify these cancer predisposition genes, in addition to clinical tumor testing research to identify these genes in patients with specific cancers.

Sources: Nature Communications, Nature Education, The Cancer Genome Atlas,

About the Author
Master's (MA/MS/Other)
Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 30, 2022
Cancer
Sedentary Lifestyle Linked to Breast Cancer Risk
Sedentary Lifestyle Linked to Breast Cancer Risk
Experts have recognized that active lifestyles favor lower breast cancer risk.  However, despite this long-standing ...
OCT 18, 2022
Genetics & Genomics
Mitochondrial DNA Can Move to the Genome to Trigger Human Evolution
Mitochondrial DNA Can Move to the Genome to Trigger Human Evolution
Mitochondria are often called the powerhouse of the cell, and these organelles are well-known for their energy-generatin ...
NOV 09, 2022
Cardiology
Less Than 5 Hours of Sleep Per Night Linked to Multiple Diseases
Less Than 5 Hours of Sleep Per Night Linked to Multiple Diseases
Getting enough sleep is an important part of lowering chronic disease risk.
NOV 13, 2022
Microbiology
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
The microbes in the human gastrointestinal tract, known as the gut microbiome, have a significant impact on out health a ...
DEC 07, 2022
Drug Discovery & Development
Mucus Eating Microbe Contributes to Major Cancer Treatment Complication
Mucus Eating Microbe Contributes to Major Cancer Treatment Complication
  Akkermansia muciniphila loves to degrade mucin, a molecule found in mucus. We’ve identified this and other ...
JAN 17, 2023
Clinical & Molecular DX
Digital PCR (dPCR) in oncology applications: when accurate counts really matter
Digital PCR (dPCR) in oncology applications: when accurate counts really matter
When it comes to detecting rare cancer-causing mutations, both sensitivity and specificity matter. In the past few years ...
Loading Comments...